Masimo has partnered with Google to develop a new reference platform for Wear OS by Google smartwatches. Meanwhile, the company has also partnered with Qualcomm for its Freedom smartwatch models. These partnerships will combine Masimo's expertise in bio-sensing technologies with Qualcomm's Snapdragon wearable platforms, aiming to streamline the development process for OEMs and enhance the capabilities of Wear OS devices.
How this reference platform will help OEMs
This new reference platform will offer OEMs a package including hardware, software, biosensors, and a companion Android smartphone app. This standardised approach will enable OEMs to more efficiently create high-performance Wear OS smartwatches with advanced health and wellness features.
Masimo's bio-sensing technologies, based on experience in hospital monitoring, will provide accurate and reliable data for various health metrics. The platform will also leverage Qualcomm's Snapdragon wearable platforms to ensure superior performance, connectivity, and power efficiency.
By adopting this reference platform, OEMs can focus on designing the physical appearance and user interface of their smartwatches while relying on Masimo and Qualcomm for the underlying technology. This approach is expected to accelerate the development of innovative and feature-rich Wear OS devices.
Why Masimo sued Apple ’s blood oxygen feature
The blood oxygen feature on the Apple Watch Series 10 is not available in the US due to an ongoing patent dispute with the medical device company Masimo. Last year, Apple was also compelled to disable the feature on the Series 9 and Ultra 2 models.
Apple has been actively defending itself in Masimo's lawsuit. In January, Apple successfully secured a similar ban on Masimo's Freedom health watch, following the earlier restriction placed on its products.
How this reference platform will help OEMs
This new reference platform will offer OEMs a package including hardware, software, biosensors, and a companion Android smartphone app. This standardised approach will enable OEMs to more efficiently create high-performance Wear OS smartwatches with advanced health and wellness features.
Masimo's bio-sensing technologies, based on experience in hospital monitoring, will provide accurate and reliable data for various health metrics. The platform will also leverage Qualcomm's Snapdragon wearable platforms to ensure superior performance, connectivity, and power efficiency.
By adopting this reference platform, OEMs can focus on designing the physical appearance and user interface of their smartwatches while relying on Masimo and Qualcomm for the underlying technology. This approach is expected to accelerate the development of innovative and feature-rich Wear OS devices.
Why Masimo sued Apple ’s blood oxygen feature
The blood oxygen feature on the Apple Watch Series 10 is not available in the US due to an ongoing patent dispute with the medical device company Masimo. Last year, Apple was also compelled to disable the feature on the Series 9 and Ultra 2 models.
Apple has been actively defending itself in Masimo's lawsuit. In January, Apple successfully secured a similar ban on Masimo's Freedom health watch, following the earlier restriction placed on its products.
You may also like
'US-India relationship had never been stronger', says Trump aide ahead of PM Modi Meeting
UP Schools Closed Today, Holiday Announced in THESE Districts Due to Incessant Rains
Uttar Pradesh: Goods train derail in Mathura
Odisha CM Majhi assures quick relief, rescue operations for flood-affected Balasore district
